Northwest Biotherapeutics (NWBO) 10-Q 10 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 07, 2015
Document Information [Line Items]
Entity Registrant Name	NORTHWEST BIOTHERAPEUTICS INC
Entity Central Index Key	1,072,379
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	NWBO
Entity Common Stock, Shares Outstanding		78,169,566
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 19,202	$ 13,390
Restricted cash - interest payments held in escrow	1,021	865
Prepaid expenses and other current assets	978	387
Total current assets	21,201	14,642
Non-current assets:
Property, plant and equipment, net	41,999	39,999
Restricted cash - interest payments held in escrow, net of current portion	739	1,760
Other assets	309	55
Total non-current assets	43,047	41,814
Total assets	64,248	56,456
Current liabilities:
Accounts payable	11,072	9,826
Accounts payable to related party	4,198	5,729
Accrued expenses (includes related party of $10 and $8 as of June 30, 2015 and December 31, 2014, respectively)	1,188	1,211
Convertible notes, net (includes related party note of $50 and $50 as of June 30, 2015 and December 31, 2014, respectively)	238	238
Note payable - in dispute	934	934
Environmental remediation liability	6,200	6,200
Derivative liability	92,716	44,742
Total current liabilities	116,546	68,880
Non-current liabilities:
Convertible note (net of deferred financing cost of $677 and $1,123 as of June 30, 2015 and December 31, 2014, respectively)	12,323	16,377
Mortgage loan (net of deferred financing cost of $780 and $862 as of June 30, 2015 and December 31, 2014, respectively)	11,401	6,128
Other accrued expenses	149	98
Total non-current liabilities	23,873	22,603
Total liabilities	140,419	91,483
Stockholders' deficit:
Preferred stock ($0.001 par value); 40,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	0	0
Common stock ($0.001 par value); 450,000,000 shares authorized; 77,727,823 and 68,957,469 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	78	69
Additional paid-in capital	557,136	485,615
Accumulated deficit	(633,799)	(520,521)
Cumulative translation adjustment	414	(190)
Total stockholders' deficit	(76,171)	(35,027)
Total liabilities and stockholders' deficit	$ 64,248	$ 56,456

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Accrued expenses, related party net (in dollars)	$ 10	$ 8
Convertible notes payable current related parties, net (in dollars)	$ 50	$ 50
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	77,727,823	68,957,469
Common stock, shares outstanding	77,727,823	68,957,469
Convertible Debt [Member]
Deferred Finance Costs, Noncurrent, Net	$ 677	$ 1,123
Mortgage Loan [Member]
Deferred Finance Costs, Noncurrent, Net	$ 780	$ 862

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - Class Of Stock [Domain] - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Research grant and other	$ 391	$ 0	$ 585	$ 0
Total revenues	391	0	585	0
Operating costs and expenses:
Research and development	29,434	21,549	49,137	41,535
General and administrative	9,811	3,878	13,133	7,576
Total operating costs and expenses	39,245	25,427	62,270	49,111
Loss from operations	(38,854)	(25,427)	(61,685)	(49,111)
Other income (expense):
Inducement expense	0	(5,089)	0	(10,340)
Change in fair value of derivative liability	(25,694)	4,684	(48,852)	(12,300)
Interest expense	(1,636)	(33)	(2,429)	(155)
Foreign currency transaction loss	(661)	0	(312)	0
Net loss	$ (66,845)	$ (25,865)	$ (113,278)	$ (71,906)
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)	$ (0.88)	$ (0.45)	$ (1.56)	$ (1.31)
Weighted average shares used in computing basic and diluted loss per share (in shares)	75,619	57,442	72,530	54,923

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net loss	$ (66,845)	$ (25,865)	$ (113,278)	$ (71,906)
Other comprehensive loss
Foreign currency translation adjustment	672	0	604	0
Total comprehensive loss	$ (66,173)	$ (25,865)	$ (112,674)	$ (71,906)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - Related Party [Domain] - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Cumulative Translation Adjustment [Member]
Cumulative translation adjustment	$ (190)
Balance at Dec. 31, 2014	(35,027)	$ 69	$ 485,615	$ (520,521)	$ (190)
Balance (in shares) at Dec. 31, 2014		68,957
Proceeds from issuance of common stock	40,000	$ 5	39,995	0	0
Proceeds from issuance of common stock (in Shares)		5,405
Redeemable securities settlement	299	$ 0	299	0	0
Redeemable securities settlement (in shares)		80
Issuance of common stock for debt conversion	4,500	$ 1	4,499	0	0
Issuance of common stock for debt conversion (in shares)		682
Issuance of common stock for conversion of accrued interest	187	$ 0	187	0	0
Issuance of common stock for conversion of accrued interest (in Shares)		20
Proceeds from warrants exercises	6,792	$ 2	6,790	0	0
Proceeds from warrants exercises (in shares)		1,612
Reclassification of warrant liabilities related to warrants exercised for cash	58	$ 0	58	0	0
Cashless warrants exercise	521	$ 1	520	0	0
Cashless warrants exercise (in shares)		569
Issuance of common stock as compensation	3,389	$ 0	3,389	0	0
Issuance of common stock as compensation (in Shares)		403
Stock compensation expense - Cognate BioServices	15,784	$ 0	15,784	0	0
Net loss	(113,278)	0	0	(113,278)	0
Balance at Jun. 30, 2015	(76,171)	$ 78	557,136	(633,799)	414
Balance (in shares) at Jun. 30, 2015		77,728
Cumulative translation adjustment	$ 414	$ 0	$ 0	$ 0	$ 604

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows from Operating Activities:
Net Loss	$ (113,278)	$ (71,906)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	15	6
Amortization of deferred financing cost	717	0
Change in fair value of derivatives	48,852	12,300
Accrued interest converted to common stock	0	76
Stock and warrants issued to Cognate BioServices as compensation under Cognate Agreements	15,784	10,623
Stock and warrants issued for services	3,389	1,722
Inducement expense	0	10,340
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(591)	(30)
Accounts payable and accrued expenses	2,211	1,385
Related party accounts payable and accrued expenses	(1,529)	7,986
Deposits and other non-current assets	(254)	0
Net cash used in operating activities	(44,684)	(27,498)
Cash Flows from Investing Activities:
Purchase of property and equipment/cost of construction in progress	(2,015)	0
Cash deposited in custody account	0	(3,414)
Net cash used in investing activities	(2,015)	(3,414)
Cash Flows from Financing Activities:
Proceeds from mortgage loan	4,997	0
Deferred offering cost related to mortgage loan	(138)	0
Proceeds transferred from escrow account	62	0
Repayment of convertible promissory notes	0	(25)
Proceeds from exercise of warrants	6,792	3,087
Proceeds from issuance common stock and warrants	0	2,059
Proceeds from issuance common stock	40,000	0
Gross proceeds from issuance common stock and overallotment rights	0	15,000
Offering costs	0	(1,105)
Net cash provided by financing activities	51,713	21,266
Effect of exchange rate changes on cash and cash equivalents	798	0
Net increase (decrease) in cash and cash equivalents	5,812	(9,646)
Cash and cash equivalents at beginning of period	13,390	18,499
Cash and cash equivalents at end of period	19,202	8,853
Supplemental disclosure of cash flow information
Interest payments on mortgage loan	(673)	0
Supplemental schedule of non-cash investing and financing activities:
Reclass of redeemable security to equity	0	8,913
Deferred offering cost related to mortgage loan	51	0
Reclassification of warrant liabilities related to cashless warrants exercise	521	0
Reclassification of warrant liabilities related to warrants exercised for cash	58	0
Interest payment on convertible note from escrow	803	0
Issuance of common stock for debt conversion	4,500	0
Issuance of common stock for conversion of accrued interest	187	0
Redeemable security settlement	299	0
Notes Payable and Accrued Expenses [Member]
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock	0	140
Cognate Bioservices [Member]
Cash Flows from Financing Activities:
Proceeds from issuance common stock and warrants	0	2,250
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock	$ 0	$ 8,835

Organization and Description of

Organization and Description of Business and Recent Developments	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Description of Business and Recent Developments Northwest Biotherapeutics, Inc. and its subsidiaries NW Bio Europe S.A.R.L, NW Bio Gmbh and Aracaris Capital, Ltd. (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company’s platform technology, DCVax®, is currently being tested for the treatment of certain types of cancers through clinical trials in the United States and Europe that are in various phases. Recent Developments During the quarter ended June 30, 2015, the Company expanded its patient recruitment in the Phase III trial of DCVax-L for Glioblastoma multiforme (GBM) brain cancer. The Company conducted further product development activities and intellectual property filings. The Company undertook legal, regulatory, scientific and operational preparatory work for multiple Phase II trials which the Company anticipates launching during the second half of the year. The Company expanded and accelerated the engineering, systems design and development, infrastructure arrangements, land use and zoning, legal and contractual, regulatory analyses and other work related to development of new manufacturing capacity in Europe. On February 13, 2015, the Company entered into a mortgage loan agreement (“the Mortgage”) with Lancashire Mortgage Corporation Limited in UK for approximately $ 5.0 18 month 12 On April 2, 2015, the Company entered into a stock purchase agreement (the “Agreement”) with Woodford Investment Management LLP as agent for the CF Woodford Equity Income Fund and other clients (collectively, “Woodford”). Pursuant to the Agreement, the Company sold 5,405,405 shares of the Company’s unregistered common stock, par value $ 0.001 7.40 40,000 11,500 28,500 In April and June of 2015, an unrelated institutional investor elected to exchange $ 4.50 5.00 701,033

Liquidity and Financial Conditi

Liquidity and Financial Condition	6 Months Ended
	Jun. 30, 2015
Liquidity [Abstract]
Liquidity and Financial Condition [Text Block]	2. Liquidity and Financial Condition During the six months ended June 30, 2015, the Company used approximately $ 44.7 113.3 68.8 The Company had cash and cash equivalents of $ 19.2 95.3 (with $ 92.7 95.3 deficit comprised of non-cash derivative liabilities) 4.2 Because of recurring operating losses, net operating cash flow deficits, and an accumulated deficit there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might become necessary should the Company be able to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2015, condensed consolidated statements of operations for the three months and six months ended June 30, 2015 and 2014, condensed consolidated statements of comprehensive loss for the three months and six months ended June 30, 2015 and 2014, condensed consolidated statement of stockholders’ equity (deficit) for the six months ended June 30, 2015, and the condensed consolidated statements of cash flows for the six months ended June 30, 2015 and 2014 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and six months ended June 30, 2015 are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on March 17, 2015. The Company reclassified debt issuance costs from other long-term assets to long-term debt, net on the condensed consolidated balance sheets for all periods presented pursuant to early adoption of Accounting Standards Update ("ASU") No. 2015-03 - Simplifying the Presentation of Debt Issuance Costs. In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of equity instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply. The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The amount of the liability resulting from the completion of the clean-up, if any, would be included in other income(expense). As of June 30, 2015, we estimate that the total environmental remediation costs associated with the purchase of the UK Facility will be approximately $ 6.2 6.2 4.5 32.0 Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs for the Company’s Phase III and Phase I/II clinical trials, related party manufacturing costs, consulting costs, contract research and development costs, and compensation costs. For the six months ended June 30, 2015 and 2014, the Company recognized research and development costs (cash and non-cash combined) of $ 49.1 41.5 6.6 3.3 1.5 2 For the six months ended June 30, 2015 and 2014, the Company made cash payments of approximately $ 21.3 (with invoices generally being paid all in cash) and $ 12.4 4.2 2.7 For the six months ended June 30, 2015 and 2014, the Company incurred non-cash equity based compensation (restricted common stock and warrants) for the ongoing vesting (in equal monthly installments over 3 under 15.8 0.9 10.6 0.9 The value of the monthly vesting amounts was higher in the six months ended June 2015 than the period ended June 2014 because the price per share of the Company’s stock has risen to $ 9.93 The Company maintains operations in Germany, the United Kingdom and Canada. Assets and liabilities are translated into U.S. dollars using end of period exchange rates and revenues and expense are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss within Shareholders’ Equity. During the six months ended June 30, 2015, the Company recorded $ 0.6 Foreign currency transaction losses are recognized in the Consolidated Statements of Operations as incurred. Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2014 Annual Report. In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-03 , Simplifying the Presentation of Debt Issuance Costs In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. Fair Value Measurements Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of the inputs used in the valuation techniques the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices for identical assets and liabilities traded in active exchange markets, such as the New York Stock Exchange. Level 2 - Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 2 also includes derivative contracts whose value is determined using a pricing model with observable market inputs or can be derived principally from or corroborated by observable market data. Level 3 - Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation; also includes observable inputs for nonbinding single dealer quotes not corroborated by observable market data. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. A model validation policy governs the use and control of valuation models used to estimate fair value. The Company performs due diligence procedures over third-party pricing service providers in order to support their use in the valuation process. Where market information is not available to support internal valuations, independent reviews of the valuations are performed and any material exposures are escalated through a management review process. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. Fair value measured at June 30, 2015 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs June 30, 2015 (Level 1) (Level 2) (Level 3) Warrant liability $ 92,716 $ - $ - $ 92,716 Fair value measured at December 31, 2014 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Warrant liability $ 44,742 $ - $ - $ 44,742 There were no transfers between Level 1, 2 or 3 during the six month period ended June 30, 2015. dated volatilities) inputs (in thousands). Warrant Liability Balance – January 1, 2015 $ 44,742 Change in fair value 48,852 Cashless warrants exercise (521) Warrants exercised for cash (58) Redeemable security settlement (299) Balance – June 30, 2015 $ 92,716 The Company’s warrant liabilities are measured at fair value using the Monte Carlo simulation valuation methodology. Date of valuation June 8, 2015* June 9, 2015* June 12, 2015* June 23, 2015* June 30, 2015 Strike price $ 5.97 $ 5.97 $ 5.97 $ 5.97 $2.40-$5.97 Volatility (annual) 66.4 % 66.4 % 66.4 % 66.4 % 66.4%-65.9 % Risk-free rate 1.2 % 1.3 % 1.3 % 1.2 % 1.0%-1.4 % Contractual term (years) 3.5 3.5 3.5 3.4 3.0-4.2 Dividend yield (per share) 0 % 0 % 0 % 0 % 0 % * Inputs for derivative warrants exercise for cash that were marked to fair value through the time of exercise. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

Stock-based Compensation- Non-E

Stock-based Compensation- Non-Employees	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5. Stock-based Compensation- Non-Employees Stock based payment expense (restricted common stock and warrants) to Cognate for the ongoing vesting over 3 Cognate services 15.8 0.9 10.6 0.9 4.4 1.5 9.93

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment June 30, December 31, 2015 2014 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 191 137 Construction in progress (property in the United Kingdom) 41,889 39,928 42,174 40,159 Less: accumulated depreciation (175) (160) $ 41,999 $ 39,999 Depreciation expense was approximately $ 15,000 6,000

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7. Notes Payable 2014 Convertible Senior Notes The 2014 Convertible Senior Notes are due on August 15, 2017 6.60 The Company has remaining $ 1.8 During the six months ended June 30, 2015, $ 4.5 701,033 Three months ended Six months ended June 30, 2015 June 30, 2015 Contractual interest $ 135 $ 351 Accelerated interest associated with the converted portion of convertible senior notes into common stock 563 563 Amortization of debt issuance costs 107 212 Accelerated amortization of debt issuance cost due to the converted portion of convertible senior notes into common stock 234 234 Total interest expense on the convertible senior notes $ 1,039 $ 1,360 Mortgage Loan On February 13, 2015, the Company entered into a mortgage loan agreement (the “Mortgage”) with Lancashire Mortgage Corporation Limited in the UK to expand the facility to $ 12 7.75 1.5 12 5 3.25 0.1 Interest expense related to the February 13, 2015 and November 17, 2014 mortgage loans amounted to $ 0.6 0.9 0.3 0.6 0.1 0.3 Other Notes Payable March 31, December 31, 2015 2014 Notes payable - current 12% unsecured originally due July 2011 - in dispute (1) $ 934 $ 934 934 934 Convertible notes payable, net - current 6% unsecured (2) 135 135 8% unsecured note due 2014 (3) 53 53 188 188 Note payable 6% due on demand (4) 50 50 50 50 Total notes payable, net $ 1,172 $ 1,172 (2) This $0.135 million note as of June 30, 2015 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents. (3) This $0.053 million note was due May 25, 2014, and is currently past due. (4) This $0.050 million demand note as of June 30, 2015 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

Potentially Dilutive Securities

Potentially Dilutive Securities	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	8. Potentially Dilutive Securities Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the three month and six month periods ended June 30, 2015 and 2014, due to net losses. For the six months ended June 30, 2015 2014 Common stock options 1,551 1,551 Over-allotment rights - 2,273 Common stock warrants - equity treatment 13,166 14,200 Common stock warrants - liability treatment 12,491 9,108 Convertible notes 2,135 81 Potentially dilutive securities 29,343 27,213

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions Cognate BioServices, Inc. Under the January 17, 2014 DCVax®-L Manufacturing Services Agreement and the DCVax-Direct Agreement, if the Company, in breach of the Agreements, shuts down or suspends its DCVax-L program or DCVax-Direct program with Cognate, the Company will be liable for certain fees in addition to any other remedies. The fees are based on the stage at which the shut down or suspension occurs: • Prior to the last dose of the last patient enrolled in the Phase III trial for DCVax®-L or after the last dose of the last patient enrolled in the Phase III clinical trial for DCVax®-L but before any submission for product approval in any jurisdiction or after the submission of any application for market authorization but prior to receiving a marketing authorization approval: in any of these cases, the fee shall be $ 3 • At any time after receiving the equivalent of a marketing authorization for DCVax®-L in any jurisdiction, the fee shall be $ 5 For the six months ended June 30, 2015, the Company made net disbursements to Cognate of approximately $ 21.3 As of June 30, 2015 and December 31, 2014, the Company owed Cognate (including third party sub-contract amounts) approximately $ 4.2 5.7 T 318,116 8.1 2.7 Of note, in accordance with ASC 718, Stock Based Compensation

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity (Deficit) Common Stock Issuances First Quarter 2015 During the quarter ended March 31, 2015, the Company issued an aggregate of 888,187 3.7 During the quarter ended March 31, 2015, the Company issued 80,068 0.3 During the quarter ended March 31, 2015, the Company issued an aggregate of 385,000 0.5 Second Quarter 2015 On April 2, 2015, the Company entered into a stock purchase agreement (the “Agreement”) with Woodford Investment Management LLP as agent for the CF Woodford Equity Income Fund and other clients (collectively, “Woodford”). Pursuant to the Agreement, the Company agreed to sell, and Woodford agreed to purchase, 5,405,405 0.001 7.40 40 1,554,054 11.5 April 8, 2015 3,851,351 28.5 May 1, 2015 During the quarter ended June 30, 2015, the Company converted $ 4.5 701,033 During the quarter ended June 30, 2015, the Company issued an aggregate of 723,422 3.1 9,200 0.06 During the quarter ended June 30, 2015, the Company issued an aggregate of 183,895 During the quarter ended June 30, 2015, the Company issued an aggregate of 85,228 0.7 During the quarter ended June 30, 2015, the Company issued an aggregate of 318,116 8.1 Stock Purchase Warrants Number of Weighted Average Warrants Exercise Price Outstanding as of December 31, 2014 29,385 $ 4.72 Warrants exercised for cash (1,611) 4.18 Warrants exercised on a cashless basis* (302) 3.94 Warrant adjustment due to Cognate price reset 62 3.35 Warrants expired and cancellation (2,134) 4.63 Adjustment related to prior issued warrants 257 4.31 Outstanding as of June 30, 2015 ** 25,657 $ 4.76 *The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities measured at fair value and re-measures these instruments at fair value each reporting period. ** Approximately 14,323,003 3.3 4.2

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	11. Subsequent Events The Company reviewed its activities and concluded that no subsequent events have occurred that would require recognition in our condensed consolidated financial statements or in the notes to our condensed consolidated financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2015, condensed consolidated statements of operations for the three months and six months ended June 30, 2015 and 2014, condensed consolidated statements of comprehensive loss for the three months and six months ended June 30, 2015 and 2014, condensed consolidated statement of stockholders’ equity (deficit) for the six months ended June 30, 2015, and the condensed consolidated statements of cash flows for the six months ended June 30, 2015 and 2014 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and six months ended June 30, 2015 are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on March 17, 2015.
Reclassification, Policy [Policy Text Block]	Reclassifications The Company reclassified debt issuance costs from other long-term assets to long-term debt, net on the condensed consolidated balance sheets for all periods presented pursuant to early adoption of Accounting Standards Update ("ASU") No. 2015-03 - Simplifying the Presentation of Debt Issuance Costs.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of equity instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.
Environmental Cost, Expense Policy [Policy Text Block]	The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The amount of the liability resulting from the completion of the clean-up, if any, would be included in other income(expense). As of June 30, 2015, we estimate that the total environmental remediation costs associated with the purchase of the UK Facility will be approximately $ 6.2 6.2 4.5 32.0
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs for the Company’s Phase III and Phase I/II clinical trials, related party manufacturing costs, consulting costs, contract research and development costs, and compensation costs. For the six months ended June 30, 2015 and 2014, the Company recognized research and development costs (cash and non-cash combined) of $ 49.1 41.5 6.6 3.3 1.5 2 For the six months ended June 30, 2015 and 2014, the Company made cash payments of approximately $ 21.3 (with invoices generally being paid all in cash) and $ 12.4 4.2 2.7 For the six months ended June 30, 2015 and 2014, the Company incurred non-cash equity based compensation (restricted common stock and warrants) for the ongoing vesting (in equal monthly installments over 3 under 15.8 0.9 10.6 0.9 The value of the monthly vesting amounts was higher in the six months ended June 2015 than the period ended June 2014 because the price per share of the Company’s stock has risen to $ 9.93
Foreign Currency Transactions and Translations Policy [Policy Text Block]	The Company maintains operations in Germany, the United Kingdom and Canada. Assets and liabilities are translated into U.S. dollars using end of period exchange rates and revenues and expense are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss within Shareholders’ Equity. During the six months ended June 30, 2015, the Company recorded $ 0.6 Foreign currency transaction losses are recognized in the Consolidated Statements of Operations as incurred.
Significant Accounting Policies [Policy Text Block]	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2014 Annual Report.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-03 , Simplifying the Presentation of Debt Issuance Costs In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of June 30, 2015 and December 31, 2014 (in thousands): Fair value measured at June 30, 2015 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs June 30, 2015 (Level 1) (Level 2) (Level 3) Warrant liability $ 92,716 $ - $ - $ 92,716 Fair value measured at December 31, 2014 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Warrant liability $ 44,742 $ - $ - $ 44,742
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table presents changes in Level 3 liabilities measured at fair value for the six month period ended June 30, 2015. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands). Warrant Liability Balance – January 1, 2015 $ 44,742 Change in fair value 48,852 Cashless warrants exercise (521) Warrants exercised for cash (58) Redeemable security settlement (299) Balance – June 30, 2015 $ 92,716
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	A summary of quantitative information about significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2015 is as follows: Date of valuation June 8, 2015* June 9, 2015* June 12, 2015* June 23, 2015* June 30, 2015 Strike price $ 5.97 $ 5.97 $ 5.97 $ 5.97 $2.40-$5.97 Volatility (annual) 66.4 % 66.4 % 66.4 % 66.4 % 66.4%-65.9 % Risk-free rate 1.2 % 1.3 % 1.3 % 1.2 % 1.0%-1.4 % Contractual term (years) 3.5 3.5 3.5 3.4 3.0-4.2 Dividend yield (per share) 0 % 0 % 0 % 0 % 0 % * Inputs for derivative warrants exercise for cash that were marked to fair value through the time of exercise.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consist of the following at June 30, 2015 and December 31, 2014 (in thousands): June 30, December 31, 2015 2014 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 191 137 Construction in progress (property in the United Kingdom) 41,889 39,928 42,174 40,159 Less: accumulated depreciation (175) (160) $ 41,999 $ 39,999

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Interest Income and Interest Expense Disclosure [Table Text Block]	The following table shows the details of interest expenses related to 2014 Convertible Senior Notes for the three and six months ended June 30, 2015 (in thousands): Three months ended Six months ended June 30, 2015 June 30, 2015 Contractual interest $ 135 $ 351 Accelerated interest associated with the converted portion of convertible senior notes into common stock 563 563 Amortization of debt issuance costs 107 212 Accelerated amortization of debt issuance cost due to the converted portion of convertible senior notes into common stock 234 234 Total interest expense on the convertible senior notes $ 1,039 $ 1,360
Schedule of Debt [Table Text Block]	Notes payable consist of the following at June 30, 2015 and December 31, 2014 (in thousands): March 31, December 31, 2015 2014 Notes payable - current 12% unsecured originally due July 2011 - in dispute (1) $ 934 $ 934 934 934 Convertible notes payable, net - current 6% unsecured (2) 135 135 8% unsecured note due 2014 (3) 53 53 188 188 Note payable 6% due on demand (4) 50 50 50 50 Total notes payable, net $ 1,172 $ 1,172 (1) This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding. (2) This $0.135 million note as of June 30, 2015 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents. (3) This $0.053 million note was due May 25, 2014, and is currently past due. (4) This $0.050 million demand note as of June 30, 2015 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

Potentially Dilutive Securiti23

Potentially Dilutive Securities (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented (in thousands): For the six months ended June 30, 2015 2014 Common stock options 1,551 1,551 Over-allotment rights - 2,273 Common stock warrants - equity treatment 13,166 14,200 Common stock warrants - liability treatment 12,491 9,108 Convertible notes 2,135 81 Potentially dilutive securities 29,343 27,213

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule Of Warrant Activity [Table Text Block]	The following is a summary of warrant activity for the six months ended June 30, 2015 (in thousands): Number of Weighted Average Warrants Exercise Price Outstanding as of December 31, 2014 29,385 $ 4.72 Warrants exercised for cash (1,611) 4.18 Warrants exercised on a cashless basis* (302) 3.94 Warrant adjustment due to Cognate price reset 62 3.35 Warrants expired and cancellation (2,134) 4.63 Adjustment related to prior issued warrants 257 4.31 Outstanding as of June 30, 2015 ** 25,657 $ 4.76 *The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities measured at fair value and re-measures these instruments at fair value each reporting period. ** Approximately 14,323,003 3.3 4.2

Organization and Description 25

Organization and Description of Business and Recent Developments (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	6 Months Ended
	May. 01, 2015	Apr. 08, 2015	Apr. 02, 2015	Feb. 13, 2015	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014
Common Stock, Par Or Stated Value Per Share			$ 0.001		$ 0.001	$ 0.001	$ 0.001
Stock Issued During Period, Value, New Issues						$ 40,000
Debt Conversion, Converted Instrument, Shares Issued					701,033
Subsequent Event [Member]
Debt Conversion, Original Debt, Amount					$ 4,500
Debt Conversion, Converted Instrument, Rate					5.00%
Debt Conversion, Converted Instrument, Shares Issued					701,033
Woodford [Member] | Subsequent Event [Member]
Common Stock, Par Or Stated Value Per Share			0.001
Sale of Stock, Price Per Share			$ 7.40
Stock Issued During Period, Value, New Issues	$ 28,500	$ 11,500	$ 40,000
Lancashire Mortgage Corporation Limited [Member]
Bridge Loan				$ 5,000
Short-term Debt, Terms				18 month
Short-term Debt, Percentage Bearing Fixed Interest Rate				12.00%

Liquidity and Financial Condi26

Liquidity and Financial Condition (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Liquidity and Financial Condition [Line Items]
Net Cash Provided By (Used In) Operating Activities	$ (44,684)	$ (27,498)
Share Based Compensation Aggregate Non Cash Charges For The Non Cash Interest Associated With The Accretion Of Our Convertible Notes Discount Net	68,800
Cash Equivalents, at Carrying Value	19,200
Current Assets Less Payables	95,300
Convertible Notes Payable Related Parties	4,200
Working Capital Deficit	113,300
Derivative Liability	92,700
Noncash Derivative Liability	$ 95,300

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Summary of Significant Accounting Policies [Line Items]
Research and Development Expense	$ 29,434	$ 21,549	$ 49,137	$ 41,535
Cash payments			21,300	12,400
Cash payments for services			4,200	2,700
Accrued Environmental Loss Contingencies, Noncurrent	6,200		6,200
Payments to Acquire in Process Research and Development			49,100	41,500
Site Contingency, Loss Exposure in Excess of Accrual, High Estimate			4,500
Site Contingency, Loss Exposure in Excess of Accrual, Low Estimate			32,000
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate			6,200
Foreign Currency Transaction Gain (Loss), Realized	$ (661)	$ 0	$ (312)	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 9.93
Cognate Bioservices [Member]
Summary of Significant Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested			$ 15,800	$ 10,600
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			0.9	0.9
Clinical Site [Member] | CRO fees [Member]
Summary of Significant Accounting Policies [Line Items]
Research and Development Expense			$ 6,600	$ 3,300
Clinical Site [Member] | Site Fees [Member]
Summary of Significant Accounting Policies [Line Items]
Research and Development Expense			$ 1,500	$ 2,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 92,716	$ 44,742
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 92,716	$ 44,742

Fair Value Measurements (Deta29

Fair Value Measurements (Details 1) - Warrant Liability [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 44,742
Change in fair value	48,852
Cashless warrants exercise	(521)
Warrants exercised for cash	(58)
Redeemable security settlement	(299)
Balance	$ 92,716

Fair Value Measurements (Deta30

Fair Value Measurements (Details 2) - Jun. 30, 2015 - $ / shares		Total
Quantitative Information One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	[1]	$ 5.97
Volatility (annual)	[1]	66.40%
Risk-free rate	[1]	1.20%
Contractual term (years)	[1]	3 years 6 months
Dividend yield (per share)	[1]	0.00%
Quantitative Information Two [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	[1]	$ 5.97
Volatility (annual)	[1]	66.40%
Risk-free rate	[1]	1.30%
Contractual term (years)	[1]	3 years 6 months
Dividend yield (per share)	[1]	0.00%
Quantitative Information Three [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	[1]	$ 5.97
Volatility (annual)	[1]	66.40%
Risk-free rate	[1]	1.30%
Contractual term (years)	[1]	3 years 6 months
Dividend yield (per share)	[1]	0.00%
Quantitative Information Four [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	[1]	$ 5.97
Volatility (annual)	[1]	66.40%
Risk-free rate	[1]	1.20%
Contractual term (years)	[1]	3 years 4 months 24 days
Dividend yield (per share)	[1]	0.00%
Quantitative Information Five [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Dividend yield (per share)		0.00%
Quantitative Information Five [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price		$ 5.97
Volatility (annual)		65.90%
Risk-free rate		1.40%
Contractual term (years)		4 years 2 months 12 days
Quantitative Information Five [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price		$ 2.40
Volatility (annual)		66.40%
Risk-free rate		1.00%
Contractual term (years)		3 years
[1]	Inputs for derivative warrants exercise for cash that were marked to fair value through the time of exercise.

Stock-based Compensation- Non31

Stock-based Compensation- Non-Employees (Details Textual) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 4.4	$ 4.4
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 9.93
Cognate Bioservices [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested		$ 15.8	$ 10.6
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		0.9	0.9

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment, Gross	$ 42,174	$ 40,159
Less: accumulated depreciation	(175)	(160)
Property, Plant and Equipment, Net	41,999	39,999
Leasehold improvements [Member]
Property, Plant and Equipment, Gross	69	69
Office furniture and equipment [Member]
Property, Plant and Equipment, Gross	25	25
Computer equipment and software [Member]
Property, Plant and Equipment, Gross	191	137
Construction in Progress [Member]
Property, Plant and Equipment, Gross	$ 41,889	$ 39,928

Property and Equipment (Detai33

Property and Equipment (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Depreciation	$ 15,000	$ 6,000

Notes Payable (Details)

Notes Payable (Details) - Jun. 30, 2015 - USD ($) $ in Thousands	Total	Total
Contractual interest	$ 135	$ 351
Accelerated interest associated with the converted portion of convertible senior notes into common stock	563	563
Amortization of debt issuance costs	107	212
Accelerated amortization of debt issuance cost due to the converted portion of convertible senior notes into common stock	234	234
Total interest expense on the convertible senior notes	$ 1,039	$ 1,360

Notes Payable (Details 1)

Notes Payable (Details 1) - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Notes payable - current		$ 934	$ 934
Convertible notes payable, net - current		238	238
Notes payable		50	50
Total notes payable, net		1,172	1,172
Notes Payable Current, Unsecured, Issued One [Member]
Debt Instrument [Line Items]
Notes payable - current	[1]	934	934
Convertible Notes Payable Current, Unsecured, Issued One [Member]
Debt Instrument [Line Items]
Convertible notes payable, net - current	[2]	135	135
Convertible Notes Payable Current Unsecured Issued Two [Member]
Debt Instrument [Line Items]
Convertible notes payable, net - current	[3]	53	53
Note Payable [Member]
Debt Instrument [Line Items]
Notes payable	[4]	$ 50	$ 50
[1]	This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding.
[2]	This $0.135 million note as of June 30, 2015 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
[3]	This $0.053 million note was due May 25, 2014, and is currently past due.
[4]	This $0.050 million demand note as of June 30, 2015 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

Notes Payable (Details Textual)

Notes Payable (Details Textual) - Subsequent Event Type [Domain] € in Thousands, $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Feb. 13, 2015USD ($)	Jun. 30, 2015USD ($)shares	Jun. 30, 2015USD ($)shares	Feb. 13, 2015EUR (€)
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 4,500
Debt Conversion, Converted Instrument, Shares Issued | shares		701,033
Interest Expense, Debt		$ 563	$ 563
Write off of Deferred Debt Issuance Cost		234	234
Mortgages [Member]
Debt Instrument [Line Items]
Interest Expense, Debt		600	900
Write off of Deferred Debt Issuance Cost		100	300
Second Mortgage [Member]
Debt Instrument [Line Items]
Short-term Debt	$ 12,000			€ 7,750
Senior Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount			$ 4,500
Debt Conversion, Converted Instrument, Shares Issued | shares			701,033
Debt Instrument, Maturity Date			Aug. 15, 2017
Debt Instrument, Convertible, Conversion Ratio			6.60
Debt Conversion, Description			701,033
Escrow Deposit		$ 1,800	$ 1,800
Notes Payable Current, Unsecured, Issued One [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.00%	12.00%
Notes Payable Current Unsecured Issued Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%	6.00%
Notes Payable Current, Unsecured, Issued Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%	8.00%
Unsecured Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%	6.00%
Bridge Loan [Member]
Debt Instrument [Line Items]
Initial Loan Amount Received	5,000			€ 3,250
Deferred Finance Costs, Net	$ 100
Bridge Loan [Member] | Second Mortgage [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%			12.00%
Debt Instrument, Term	1 year 6 months
12% Coupon [Member] | Mortgages [Member]
Debt Instrument [Line Items]
Interest Expense, Debt		$ 300	$ 600

Potentially Dilutive Securiti37

Potentially Dilutive Securities (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Potentially dilutive securities	29,343	27,213
Common stock options [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Potentially dilutive securities	1,551	1,551
Over-allotment rights [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Potentially dilutive securities	0	2,273
Common stock warrants - equity treatment [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Potentially dilutive securities	13,166	14,200
Common stock warrants - liability treatment [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Potentially dilutive securities	12,491	9,108
Convertible notes [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Potentially dilutive securities	2,135	81

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 3,389
Common Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross	0
Cognate Bioservices [Member]
Related Party Transaction [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross	4,200	$ 5,700
One Time Charges Of Service Agreement	21,300
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 2,700
Stock Issued During Period, Shares, Issued for Services	8,100,000
Cognate Bioservices [Member] | Condition Two [Member]
Related Party Transaction [Line Items]
Contingent Liability DCVax-L Manufacturing Services Agreement Amount	$ 3,000
Cognate Bioservices [Member] | Condition Three [Member]
Related Party Transaction [Line Items]
Contingent Liability DCVax-L Manufacturing Services Agreement Amount	$ 5,000
Cognate Bioservices [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services	318,116

Stockholders' Equity (Deficit39

Stockholders' Equity (Deficit) (Details) - 6 months ended Jun. 30, 2015 shares in Thousands		$ / Unitshares
Shareholders Deficit [Line Items]
Number of Warrants, Outstanding as of December 31, 2014		29,385
Number of Warrants, Warrants exercised for cash		(1,611)
Number of Warrants, Warrants exercised on a cashless basis	[1]	(302)
Number of Warrants, Warrant adjustment due to Cognate price reset		62
Number of Warrants, Expired in first quarter of 2015		(2,134)
Number of Warrants, Adjustment related to prior issued warrants		257
Number of Warrants, Outstanding as of March 31, 2015	[2]	25,657
Weighted Average Exercise Price - Outstanding as of December 31, 2014 | $ / Unit		4.72
Weighted Average Exercise Price - Warrants exercised for cash | $ / Unit		4.18
Weighted average exercise Price - Warrants exercised on a cashless basis | $ / Unit	[1]	3.94
Weighted Average Exercise Price - Warrant adjustment due to Cognate price reset | $ / Unit		3.35
Weighted Average Exercise Price - Expired in first quarter of 2015 | $ / Unit		4.63
Weighted Average Exercise Price - Adjustment related to prior issued warrants | $ / Unit		4.31
Weighted Average Exercise Price - Outstanding as of March 31, 2015 | $ / Unit	[2]	4.76
[1]	The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities measured at fair value and re-measures these instruments at fair value each reporting period.
[2]	Approximately 14,323,003 warrants issued to Cognate, during the 8-year period from 2008 through 2015, with a weighted average exercise price and remaining contractual term of $3.3 and 4.2 years, respectively. The weighted average exercise price gives effect to adjustments related to the most favored nation clause in these warrants

Stockholders' Equity (Deficit40

Stockholders' Equity (Deficit) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended		6 Months Ended		84 Months Ended
	May. 01, 2015	Apr. 08, 2015	Apr. 02, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Shareholders Deficit [Line Items]
Fair value of Warrants at Issuance Date					$ 500			$ 500
Shares Issued, Price Per Share			$ 7.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					888,187
Proceeds from Warrant Exercises				$ 3,100	$ 3,700	$ 6,792	$ 3,087
Debt Conversion, Converted Instrument, Amount				$ 4,500
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 3,389
Warrants Issued During Period								14,323,003
Warrants Issued, Weighted Average Exercise Price Per Warrant								$ 3.3
Warrants Issued, Weighted Average Remaining Contractual Term								4 years 2 months 12 days
Fair Value Of Common Stock Issued For Redemption of Redeemable Securities					$ 300
Stock Issued During Period, Shares, Other					80,068
Stock Issued During Period, Shares, Cashless Exercise of Warrants					385,000
Stock Issued During Period, Shares, Acquisitions			5,405,405
Common Stock, Par Or Stated Value Per Share			$ 0.001	$ 0.001		$ 0.001			$ 0.001
Stock Issued During Period, Value, Acquisitions			$ 40,000
Stock Issued During Period, Exercise Of Warrants				723,422
Stock Issued During Period, Shares, Extinguishment of warrant liabilities				9,200
Stock Issued During Period, Value, Extinguishment of warrant liabilities				$ 60
Debt Conversion, Converted Instrument, Shares Issued				701,033
Sale of Stock Closing One [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Acquisitions	3,851,351	1,554,054
Stock Issued During Period, Value, Acquisitions	$ 28,500	$ 11,500
Sale of Stock, Transaction Date	May 1, 2015		Apr. 8, 2015
Cognate Bioservices [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services						8,100,000
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 2,700
Stock Issued During Period, Shares, Share-based Compensation, Gross						318,000
Multiple Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Exercise Of Warrants				183,895
individual Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period Shares Exercise of Warrant						85,228
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 700
Stock Issued During Period, Shares, Share-based Compensation, Gross						85,000
Common Stock [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 0
Stock Issued During Period, Shares, Share-based Compensation, Gross						403,000
Common Stock [Member] | Cognate Bioservices [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services						318,116